Potential of Proliferative Markers in Pancreatic Cancer Management: A Systematic Review
Authors:
- Aryan Salahi‐NiriASAryan Salahi‐Niri
- Paniz ZarandPZPaniz Zarand
- Negar MansouriNMNegar Mansouri
- Omid YazdaniOYOmid Yazdani
- Romina EsbatiRERomina Esbati
- Fatemeh ShojaeianFSFatemeh Shojaeian
- Behnaz JahanbinBJBehnaz Jahanbin
- Zhaleh MohsenifarZMZhaleh Mohsenifar
- Hamid Asadzadeh AghdaeiHAHamid Asadzadeh Aghdaei
- Farid Azmoudeh ArdalanFAFarid Azmoudeh Ardalan
- Seyed Amir Ahmad Safavi‐NainiSSSeyed Amir Ahmad Safavi‐Naini
Open Access
- 5 March 2025
- journal article
- review article
- Published by Wiley in Health Science Reports
- Vol. 8 (3) , e70412
Abstract
Background and Aims: Pancreatic cancer is an aggressive malignancy with poor prognosis and limited treatment options. Chemotherapy remains a primary therapeutic approach, but patient responses vary significantly, emphasizing the need for reliable biomarkers. This review explores the potential role of proliferative markers, including Ki‐67, PCNA, Cyclin D1, and PHH3, as predictive and prognostic indicators in pancreatic cancer management, aiming to enhance personalized treatment strategies.Methods: We conducted a narrative review by searching Scopus, PubMed, and Google Scholar for studies focusing on Ki‐67, PCNA, Cyclin D1, and PHH3 in relation to pancreatic cancer and chemotherapy. The literature was reviewed to evaluate the role of these markers in predicting chemotherapy response, tumor progression, and overall patient survival.Results: The review highlights the clinical significance of these markers. Ki‐67 and PCNA are associated with cell proliferation, while Cyclin D1 regulates cell cycle progression and PHH3 is linked to mitotic activity. High expression levels of these markers often correlate with increased tumor aggressiveness and poorer patient outcomes. Moreover, they show promise in predicting chemotherapy response, which can inform tailored therapeutic strategies. However, challenges remain, including standardization of detection methods and determination of optimal cutoff values.Conclusion: Proliferative markers such as Ki‐67, PCNA, Cyclin D1, and PHH3 hold potential as predictive and prognostic tools in pancreatic cancer management. Their integration into clinical practice could improve the accuracy of treatment decisions and enhance patient outcomes. Further research and validation are necessary to overcome existing challenges and optimize their application in personalized oncology.Keywords
This publication has 124 references indexed in Scilit:
- Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia.2001
- Cell Cycle Effects of Nonsteroidal Anti-Inflammatory Drugs and Enhanced Growth Inhibition in Combination with Gemcitabine in Pancreatic Carcinoma CellsThe Journal of Pharmacology and Experimental Therapeutics, 2001
- Prognostic value of Ki-67 expression in localized cutaneous malignant melanomaJournal of the American Academy of Dermatology, 2000
- The Ki-67 protein: From the known and the unknownJournal of Cellular Physiology, 2000
- Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas.1999
- Increased Cyclin D1 in Human Pancreatic Cancer Is Associated with Decreased Postoperative SurvivalOncology, 1998
- Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.Journal of Clinical Investigation, 1998
- Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis.1997
- PCNA: structure, functions and interactionsOncogene, 1997
- The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins.Journal of Cell Biology, 1993